Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T
Phase 1/1b trial demonstrates improved responses in relapsed large B-cell lymphoma with azer-cel and low-dose IL-2, suggesting a new treatment approach.
Key Points
To evaluate the clinical activity and safety of azer-cel combined with low-dose IL-2 in patients with relapsed large B-cell lymphoma after prior autologous CAR T therapy.
Phase 1/1b clinical trial
Patients with relapsed CD19+ large B-cell lymphoma received azer-cel and low-dose IL-2
Lymphodepletion was performed with fludarabine and cyclophosphamide
Responses were assessed using PET-CT and Lugano criteria
Overall response rate was 75% with complete response rate of 50%
Median tumor burden was 13.95 cm2 at baseline
Low-dose IL-2 improved pharmacokinetic metrics compared to azer-cel alone
Cytokine release syndrome occurred in 67% of patients, all Grade 1-2